---
title: "药明合联公告称，拟发行 2413.4 万股认购股份，每股 58.85 港元，总代价约为 14.2 亿港元。"
description: "药明合联公告称，拟发行 2413.4 万股认购股份，每股 58.85 港元，总代价约为 14.2 亿港元。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/255687807.md"
published_at: "2025-09-03T00:08:58.000Z"
---

# 药明合联公告称，拟发行 2413.4 万股认购股份，每股 58.85 港元，总代价约为 14.2 亿港元。

药明合联公告称，拟发行 2413.4 万股认购股份，每股 58.85 港元，总代价约为 14.2 亿港元。

### Related Stocks

- [02268.HK - 药明合联](https://longbridge.com/zh-CN/quote/02268.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy | Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy | [Link](https://longbridge.com/zh-CN/news/275736820.md) |
| Wuxi XDC Cayman Says FY Revenue Expected To Increase By More Than 45% | WuXi XDC Cayman Inc :FY REVENUE EXPECTED TO INCREASE BY MORE THAN 45%SEES FY NET PROFIT TO INCREASE BY MORE THAN 38% | [Link](https://longbridge.com/zh-CN/news/272576507.md) |
| WuXi XDC Dispatches Offer Document for Cash Takeover of TOT BIOPHARM | WuXi XDC Cayman Inc. has sent out an offer document for a voluntary cash takeover of TOT BIOPHARM International Co. Ltd. | [Link](https://longbridge.com/zh-CN/news/275675866.md) |
| WuXi XDC Delays Dispatch of Composite Document for Voluntary Cash Offers | WuXi XDC Cayman, Inc. (HK:2268) has announced a delay in dispatching a composite offer document for voluntary cash offer | [Link](https://longbridge.com/zh-CN/news/274833570.md) |
| CICC Sticks to Its Buy Rating for WuXi XDC Cayman, Inc. (2268) | In a report released yesterday, from CICC maintained a Buy rating on WuXi XDC Cayman, Inc., with a price target of HK$88 | [Link](https://longbridge.com/zh-CN/news/272788694.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。